PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics has achieved a milestone by completing the dosing of the fourth patient cohort in their Single Ascending Dose study for a pioneering drug targeting Retinitis Pigmentosa type 11 (RP11), a genetic blinding disease in children. The company is poised to initiate a Multiple Ascending Dose study, with the end goal of submitting a New Drug Application by 2027 for this potential treatment, addressing a market with over $1 billion annual potential.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
